VPTDF (VentriPoint Diagnostics) Debt-to-Equity: -0.63 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VPTDF VentriPoint Diagnostics Ltd VPTDF
11 GF Score
Price $0.08
! 4 Warning Signs
View Full Analysis

What is VentriPoint Diagnostics Debt-to-Equity?

VentriPoint Diagnostics VPTDF +0.61% 11 Debt-to-Equity is -0.63 as of Dec. 2025. GuruFocus rates VPTDF with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 705 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks worse than 141843.83% on this metric.

VentriPoint Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $1.81 Mil. VentriPoint Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.08 Mil. VentriPoint Diagnostics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-2.98 Mil. VentriPoint Diagnostics's debt to equity for the quarter that ended in Dec. 2025 was -0.63.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for VentriPoint Diagnostics's Debt-to-Equity or its related term are showing as below:

VPTDF' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.63   Med: -0.36   Max: 2.17
Current: -0.63

During the past 13 years, the highest Debt-to-Equity Ratio of VentriPoint Diagnostics was 2.17. The lowest was -0.63. And the median was -0.36.

VPTDF's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.23 vs VPTDF: -0.63

VentriPoint Diagnostics  (OTCPK:VPTDF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

VentriPoint Diagnostics Debt-to-Equity Related Terms

VentriPoint Diagnostics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for VentriPoint Diagnostics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VentriPoint Diagnostics Debt-to-Equity Chart

VentriPoint Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.10 2.16 -0.55 -0.63

VentriPoint Diagnostics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -0.60 -0.55 -0.50 -0.63

VPTDF vs ABT, SYK, MDT: Debt-to-Equity Comparison

For the Medical Devices subindustry, VentriPoint Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VentriPoint Diagnostics Debt-to-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where VentriPoint Diagnostics's Debt-to-Equity falls into.


VPTDF
11GF Score
VentriPoint Diagnostics Ltd VPTDF
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VentriPoint Diagnostics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

VentriPoint Diagnostics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.809 + 0.083) / -2.984
=-0.63

VentriPoint Diagnostics's Debt to Equity Ratio for the quarter that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.809 + 0.083) / -2.984
=-0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.63 mean?
VentriPoint Diagnostics (VPTDF) has a Debt-to-Equity of -0.63 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on VentriPoint Diagnostics and its competitors. According to the industry distribution chart, VentriPoint Diagnostics ranks #999999 out of 705 companies in the Medical Devices & Instruments industry.
Is VentriPoint Diagnostics' Debt-to-Equity too high?
VentriPoint Diagnostics' current Debt-to-Equity is -0.63. Based on the distribution chart, VentriPoint Diagnostics ranks #999999 out of 705 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, VentriPoint Diagnostics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does VentriPoint Diagnostics' Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #999999 out of 705 companies for Debt-to-Equity. This places VentriPoint Diagnostics in the lower half of its industry. The industry median Debt-to-Equity is 0.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on VentriPoint Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VentriPoint Diagnostics's current Debt-to-Equity is -0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current Debt-to-Equity of -0.63. The current Debt-to-Equity is -0.63. VentriPoint Diagnostics' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current Debt-to-Equity is -0.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VentriPoint Diagnostics Business Description

Other Exchanges VPT:Canada
Address 18 Hook Avenue, Unit 101, Toronto, ON, CAN, M6P 1T4
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
11GF Score

Get the complete analysis for VPTDF

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price